Clinical Trials Using Docetaxel

Clinical trials are research studies that involve people. The clinical trials on this list are studying Docetaxel. All trials on the list are supported by NCI.

NCI’s basic information about clinical trials explains the types and phases of trials and how they are carried out. Clinical trials look at new ways to prevent, detect, or treat disease. You may want to think about taking part in a clinical trial. Talk to your doctor for help in deciding if one is right for you.

Trials 76-100 of 104

  • Gemcitabine, Docetaxel, and Hydroxychloroquine in Treating Participants with Recurrent or Refractory Osteosarcoma

    This phase I / II trial studies the side effects and best dose of hydroxychloroquine and how well it works when given together with gemcitabine and docetaxel in treating participants with osteosarcoma that has come back or does not respond to treatment. Drugs used in chemotherapy, such as gemcitabine, docetaxel, and hydroxychloroquine, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading.
    Location: M D Anderson Cancer Center, Houston, Texas

  • Docetaxel, Carboplatin, and Rucaparib Camsylate in Treating Patients with Metastatic Castration Resistant Prostate Cancer with Homologous Recombination DNA Repair Deficiency

    This phase II trial studies how well docetaxel with carboplatin followed by rucaparib camsylate works in treating patients with metastatic castration resistant prostate cancer (spread outside of prostate and resistant to testosterone suppression) with homologous recombination DNA repair deficiency. Chemotherapy drugs, such as docetaxel and carboplatin, work to stop the growth of cancer cells by stopping them from dividing or spreading. Rucaparib camsylate may stop the growth of tumor cells with defects in the ability to repair mistakes in DNA by forcing additional errors so that the cancer cells cannot overcome the number of errors and will then die. Giving induction docetaxel and carboplatin followed by maintenance rucaparib camsylate may work better in treating patients with castration resistant prostate cancer.
    Location: Fred Hutch / University of Washington Cancer Consortium, Seattle, Washington

  • HER2 Directed Dendritic Cell Vaccine, Trastuzumab, Pertuzumab, and Chemotherapy in Treating Participants with Stage II-III HER-2 Positive Breast Cancer

    This early phase I trial studies how well a HER2 directed dendritic cell vaccine, trastuzumab, pertuzumab, and chemotherapy work in treating participants with stage II-III HER-2 positive breast cancer. Dendritic cells are immune cells that can tell the immune system to fight infection. Vaccines made from a person's dendritic cells may help the body build an effective immune response to kill tumor cells that express HER2. Trastuzumab is a form of “targeted therapy” because it works by attaching itself to specific molecules (receptors) on the surface of cancer cells, known as HER2 receptors. When trastuzumab attaches to HER2 receptors, the signals that tell the cells to grow are blocked and the cancer cell may be marked for destruction by the body’s immune system. Monoclonal antibodies, such as pertuzumab, may interfere with the ability of tumor cells to grow and spread. Drugs used in chemotherapy, such as docetaxel and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving a HER2 directed dendritic cell vaccine, trastuzumab, pertuzumab, and chemotherapy may work better in participants with HER-2 positive breast cancer.
    Location: Moffitt Cancer Center, Tampa, Florida

  • Pembrolizumab and Docetaxel in Treating Participants with Poorly Chemo-Responsive and Unresectable Thyroid and Salivary Gland Cancers

    This phase II trial studies how well pembrolizumab and docetaxel work in treating participants with poorly chemo-responsive thyroid and salivary gland cancers that cannot be removed by surgery. Monoclonal antibodies, such as pembrolizumab, may interfere with the ability of tumor cells to grow and spread. Drugs used in chemotherapy, such as docetaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, stopping them from dividing, or by stopping them from spreading. Giving pembrolizumab and docetaxel may work better in treating participants with thyroid and salivary gland cancers.
    Location: University of Chicago Comprehensive Cancer Center, Chicago, Illinois

  • Degarelix, Bicalutamide, and Docetaxel before Surgery in Treating Patients with High Risk Metastatic Prostate Cancer

    This pilot early phase I trial studies how well degarelix, bicalutamide, and docetaxel before surgery works in treating patients with high risk prostate. Hormone therapy using degarelix and bicalutamide, may fight prostate cancer by lowering the amount of testosterone the body makes. Drugs used in chemotherapy, such as docetaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving degarelix, bicalutamide, and docetaxel before surgery may work better in treating patients with prostate cancer.
    Location: University of Wisconsin Hospital and Clinics, Madison, Wisconsin

  • Pevonedistat and Docetaxel in Treating Patients with Stage IV or Recurrent Non-small Cell Lung Cancer

    This phase II trial studies how well pevonedistat and docetaxel work in treating patients with stage IV non-small cell lung cancer or non-small cell lung cancer that has come back. Pevonedistat may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as docetaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving pevonedistat and docetaxel may work better in treating patients with non-small cell lung cancer.
    Location: University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan

  • PTC596 in Treating Patients with Newly Diagnosed Unresectable Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Receiving Chemotherapy

    This phase Ib trial studies the side effects and best dose of PTC596 in treating patients with newly diagnosed ovarian, fallopian tube, or primary peritoneal cancer that cannot be removed by surgery who are receiving standard of care chemotherapy. PTC596 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
    Location: University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma

  • Paclitaxel, Carboplatin, and Galunisertib in Treating Patients with Newly Diagnosed, Persistent, or Recurrent Uterine, Ovarian, Fallopian Tube, or Peritoneal Carcinosarcoma

    This phase Ib trial studies the side effects and how well paclitaxel, carboplatin, and galunisertib work in treating patients with uterine, ovarian, fallopian tube, or peritoneal carcinosarcoma that is newly diagnosed, does not go to remission despite treatment (persistent), or has come back (recurrent). Drugs used in chemotherapy, such as paclitaxel and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Galunisertib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving paclitaxel, carboplatin, and galunisertib may work better in treating patients with uterine, ovarian, fallopian tube, or peritoneal carcinosarcoma.
    Location: University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma

  • Nivolumab with or without Ipilimumab or Chemotherapy in Treating Patients with Previously Untreated Stage I-IIIA Non-small Cell Lung Cancer

    This phase II trial studies how well nivolumab works when given alone and in combination with ipilimumab or chemotherapy in treating patients with previously untreated stage I-IIIA non-small cell lung cancer. Immunotherapy with monoclonal antibodies, such as nivolumab and ipilimumab, may help the body's immune system attack the tumor, and may interfere with the ability of tumor cells to grow and spread. Drugs used in chemotherapy, such as cisplatin, docetaxel, and pemetrexed, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving nivolumab with ipilimumab or chemotherapy may work better in treating patients with non-small cell lung cancer compared to chemotherapy alone.
    Location: M D Anderson Cancer Center, Houston, Texas

  • Bemcentinib and Docetaxel in Treating Patients with Stage IV Non-small Cell Lung Cancer

    This phase I trial studies the side effects and best dose of bemcentinib when given together with docetaxel in treating patients with stage IV non-small cell lung cancer. Bemcentinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as docetaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving bemcentinib and docetaxel may work better in treating patients with non-small cell lung cancer.
    Location: 2 locations

  • Study of OSE2101 Versus Standard Treatment as 2nd or 3rd Line in HLA-A2 Positive Patients With Advanced NSCLC After Failure of Immune Checkpoint Inhibitor

    The aim of this study is to determine if the Investigational Medicinal Product Tedopi (OSE2101) is more effective than standard treatment in treating patients with stage IIIB NSCLC unsuitable for radiotherapy or metastatic NSCLC in second- or third-line treatment after failure of immune checkpoint-inhibitor regimens.
    Location: MedStar Georgetown University Hospital, Washington, District of Columbia

  • Docetaxel and Carboplatin in Treating Patients with Metastatic, Castration Resistant Prostate Cancer Containing Inactivated Genes in the BRCA 1 / 2 Pathway

    This pilot phase II trial studies docetaxel and carboplatin in treating patients with castration resistant prostate cancer that has spread from the primary site (place where it started) to other places in the body (metastatic) and contains inactivated genes in the BRCA 1 / 2 pathway. Drugs used in chemotherapy, such as docetaxel and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading.
    Location: Fred Hutch / University of Washington Cancer Consortium, Seattle, Washington

  • Radiation Therapy with Cisplatin or Docetaxel and Cetuximab in Treating Patients with Stage III-IVB Head and Neck Cancer

    This randomized phase II trial studies how well radiation therapy in combination with cisplatin or docetaxel and cetuximab works in treating patients with stage III-IVB head and neck cancer. Radiation therapy uses high energy x rays to kill tumor cells. Docetaxel is designed to stop the growth of cancer cells, which may cause the cells to die. It may also damage blood vessels in tumor tissue. Cetuximab is designed to prevent or slow down the growth of cancer cells by blocking proteins inside the cancer cell, called the epidermal growth factor receptor (EGFR). Cisplatin has a platinum atom at its center. The platinum may poison the cancer cells, which may cause them to die. It is not yet known whether radiation therapy is more effective when given with cisplatin or docetaxel and cetuximab in treating patients with head and neck cancer.
    Location: University of Pittsburgh Cancer Institute (UPCI), Pittsburgh, Pennsylvania

  • Metformin Hydrochloride and Combination Chemotherapy in Treating Patients with Stage III-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

    This partially randomized phase II trial studies how well metformin hydrochloride and combination chemotherapy work in treating patients with stage III-IV ovarian, fallopian tube, or primary peritoneal cancer. Drugs used in chemotherapy, such as carboplatin, paclitaxel and docetaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Metformin hydrochloride may help carboplatin, paclitaxel and docetaxel work better by making tumor cells more sensitive to the drugs. Studying samples of blood and tissue in the laboratory from patients receiving metformin hydrochloride may help doctors learn more about the effects of metformin hydrochloride on cells. It may also help doctors understand how well patients respond to treatment. Giving metformin hydrochloride together with combination chemotherapy may kill more tumor cells.
    Location: 12 locations

  • Vorinostat, Gemcitabine Hydrochloride, and Docetaxel in Treating Patients with Soft Tissue Sarcoma That is Metastatic or Cannot Be Removed By Surgery

    This phase I / II trial studies the side effects and best dose of vorinostat when given together with gemcitabine hydrochloride and docetaxel and to see how well they work in treating patients with soft tissue sarcoma that has spread to other places in the body (metastatic) or cannot be removed by surgery. Vorinostat may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as gemcitabine hydrochloride and docetaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving vorinostat with combination chemotherapy may kill more tumor cells than giving either one alone.
    Location: University of Pittsburgh Cancer Institute (UPCI), Pittsburgh, Pennsylvania

  • A Safety Extension Study of Trastuzumab Emtansine in Participants Previously Treated With Trastuzumab Emtansine Alone or in Combination With Other Anti-Cancer Therapy in One of the Parent Studies

    This is a global, multicenter, open-label safety extension study. Participants receiving single-agent trastuzumab emtansine or trastuzumab emtansine administered in combination with other anti-cancer therapies in a Genentech / Roche-sponsored parent study who are active and receiving benefit at the closure of parent study are eligible for continued treatment in this study.
    Location: Translational Research In Oncology - US Inc, Los Angeles, California

  • Docetaxel, Cisplatin and Fluorouracil in Treating Patients with Previously Untreated Stage II-IV Nasal Cavity and Paranasal Sinus Cancer

    This phase II trial studies how well docetaxel, cisplatin and fluorouracil work in treating patients with previously untreated stage II-IV nasal cavity and / or paranasal sinus cancer. Drugs used in chemotherapy, such as docetaxel, cisplatin and fluorouracil, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading.
    Location: M D Anderson Cancer Center, Houston, Texas

  • Lenvatinib (E7080 / MK-7902) in Combination With Pembrolizumab (MK-3475) vs. Standard Chemotherapy and Lenvatinib Monotherapy in Participants With Recurrent / Metastatic Head and Neck Squamous Cell Carcinoma That Progressed After Platinum Therapy and Immunotherapy (MK-7902-009 / E7080-G000-228 / LEAP-009)

    This study is designed to assess the safety and efficacy of lenvatinib in combination with pembrolizumab versus standard of care (SOC) chemotherapy, and to also assess the safety and efficacy of lenvatinib monotherapy in participants with recurrent / metastatic head and neck squamous cell carcinoma (R / M HNSCC) that have progressed after platinum therapy and a programmed cell death protein 1 (PD-1) or anti-programmed death ligand 1 (PD-L1) inhibitor. The primary hypothesis is that pembrolizumab + lenvatinib is superior to SOC chemotherapy with respect to ORR per modified Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 as assessed by blinded independent central review.
    Location: 5 locations

  • A Multinational, Randomized, Open-Label Study of Custirsen In Patients With Advanced or Metastatic (Stage IV) Non-Small Cell Lung Cancer

    The primary objective of the study is to compare overall survival of patients randomized to receiving custirsen in combination with docetaxel (Arm A) with patients randomized to receive docetaxel alone (Arm B).
    Location: See Clinical Trials.gov

  • Comparing the New Anti-cancer Drug Eribulin with or without Chemotherapy Against the Usual Chemotherapy Alone in Metastatic Urothelial Bladder Cancer

    This phase III trial compares the new anti-cancer drug eribulin with or without chemotherapy and to see how well they work in treating patients with urothelial bladder cancer that has spread to other places in the body (metastatic). Chemotherapy drugs, such as eribulin, gemcitabine, docetaxel, and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. This trial aims to see whether adding eribulin to standard of care chemotherapy may work better in treating patients with metastatic urothelial bladder cancer.
    Location: Location information is not yet available.

  • Docetaxel with or without Bintrafusp Alfa for the Treatment of Advanced Non-small Cell Lung Cancer

    This phase II trial studies how well docetaxel works with or without bintrafusp alfa in treating patients with non-small cell lung cancer that has spread to other places in the body (advanced). Chemotherapy drugs, such as docetaxel, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Immunotherapy with bintrafusp alfa, may induce changes in body’s immune system and may interfere with the ability of tumor cells to grow and spread. Giving docetaxel and bintrafusp alfa in combination may work better in treating non small-cell lung cancer compared to docetaxel alone.
    Location: 3 locations

  • Avelumab and Docetaxel in Treating Patients with Platinum Refractory or Ineligible Metastatic Urothelial Cancer

    This phase Ib trial studies the best dose of avelumab and how well it works when given together with docetaxel in treating patients with urothelial cancer that has spread to other places in the body and does not respond to platinum chemotherapy or cannot receive platinum chemotherapy. Immunotherapy with monoclonal antibodies, such as avelumab, may help the body’s immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Drugs used in chemotherapy, such as docetaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving avelumab and docetaxel may work better in treating patients with locally advanced or metastatic urothelial cancer.
    Location: University of Iowa / Holden Comprehensive Cancer Center, Iowa City, Iowa

  • M6620 and Carboplatin with or without Docetaxel in Treating Patients with Metastatic Castration-Resistant Prostate Cancer

    This phase II trial studies how well berzosertib (M6620) and carboplatin with or without docetaxel works in treating patients with castration-resistant prostate cancer that has spread to other places in the body (metastatic). M6620 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as carboplatin and docetaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving M6620, carboplatin and docetaxel may work better in treating patients with metastatic castration-resistant prostate cancer compared to carboplatin and docetaxel alone.
    Location: 21 locations

  • Docetaxel or Paclitaxel in Reducing Chemotherapy-Induced Peripheral Neuropathy in African American Patients with Stage I-III Breast Cancer

    This phase II trial studies how well docetaxel or paclitaxel work in reducing chemotherapy-induced peripheral neuropathy in African American patients with stages I-III breast cancer. Drugs used in chemotherapy, such as docetaxel and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. It is not yet known whether giving docetaxel or paclitaxel may work better than other methods in reducing chemotherapy-induced peripheral neuropathy in patients with breast cancer.
    Location: 392 locations

  • Biomarker-Driven Therapy and Immunotherapy in Screening Participants with Recurrent or Stage IV Non-Small Cell Lung Cancer (The Expanded Lung-MAP Screening Trial)

    This expansion of the screening and multi-sub-study Lung-MAP trial is motivated by the changing landscape due to progress in the development of immunotherapies. The Lung-MAP trial was originally opened in June of 2014 for second-line treatment of participants with stage IV squamous lung cancer or squamous lung cancer that has come back (recurrent). The trial was amended to allow all participants with previously-treated stage IV or recurrent squamous lung cancer in 2015. The study is now expanding to allow participants with all types of previously-treated stage IV or recurrent non-small cell lung cancer. The type of cancer trait (biomarker) will determine to which sub-study, within this protocol, a participant will be assigned in order to compare new targeted cancer therapy designed to block the growth and spread of cancer, with the ultimate goal of being able to approve new targeted therapies in this setting. In addition, the protocol includes “non-match” sub-studies which will include all screened participants not eligible for any of the biomarker-driven sub-studies.
    Location: 785 locations